First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial – Wall Street Journal
|
First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial
Wall Street Journal ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis … |
